Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 14, 2019 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium

ROCKVILLE, Md., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
December 06, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline

ROCKVILLE, Md., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
December 03, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors

ROCKVILLE, Md., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
November 14, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Announces Leadership Transition

Douglas Swirsky Assumes Role of Chief Executive Officer ROCKVILLE, Md., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical...
November 05, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Reports Third Quarter 2018 Financial Results

ROCKVILLE, Md., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
October 17, 2018 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Announces $7.5 Million Registered Direct Offering

ROCKVILLE, Md., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced it has entered into definitive agreements with institutional investors to purchase...
October 02, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer

Combination of RX-3117 and Abraxane Appears Safe and Well-Tolerated When Administered at the Recommended Phase 2 Dose of RX-3117 and the Maximal Labeled Dose of Abraxane Preliminary Efficacy was...
September 18, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium

ROCKVILLE, Md., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the...
August 30, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

ROCKVILLE, Md., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
August 21, 2018 08:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

ROCKVILLE, Md. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...